Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3312 in advanced solid tumors
NCT04045496Phase 1Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sitneprotafib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and 4 more, sponsored by Jacobio Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 2 years and Recommended Phase 2 Dose at 2 years. Started Sep 2019; status: completed.
02
Drugs
sitneprotafib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)Esophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04045496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045496.